Online Inquiry


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Smarter™ 7 × 19 CAR Construction Service

CAR engineered T cell therapy has developed rapidly in recent years. Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against solid tumors has lagged, potentially due to insufficient CAR-T cell expansion and persistence. To improve CAR-T cell efficacy, Creative Biolabs is proud to present a new generation CAR-T cells to express interleukin (IL)-7 and CCL19 (7 × 19 CAR-T cells), as these factors are essential for the maintenance of T-cell zones in lymphoid organs, with superior anti-tumor activity compared to conventional CAR-T cells.

Introduction of 7 × 19 CAR

Studies have shown that IL-7 and CCL19 are produced by T-region fibroblast reticulocytes, which are essential for the formation and maintenance of T-cell regions in lymphoid organs, in which T cells and DCs can be recruited from the periphery. Therefore, to improve CAR-T cell efficacy, we develop potent functional elements based on IL-7 and CCL19 signaling domains, which can mimic the function of T-zone reticular cells, and recruit T cells and DCs to tumor tissues to improve the therapeutic effect of CAR-T cells against solid tumors.

To obtain 7 × 19 CAR constructs, we generate a tandem construct encoding the CAR, IL-7, and CCL19 with two 2A peptide sequence between the genes. This novel, regulatable 7 × 19 system may promote the infiltration of dendritic cells (DC) and T cells into tumor tissues.

Schematic Schemas of conventional (Conv.) and 7×19 CAR (7×19) gene constructs.

Fig.1 Schematic Schemas of conventional (Conv.) and 7×19 CAR (7×19) gene constructs. (Adachi, 2018)

Features of our 7 × 19 CAR Service

  • Strong efficacy in both solid and liquid tumors with greater tumor penetration
  • Improved safety profile including moderate cytokine secretion and decreased off-tumor toxicity
  • Excellent expert team for offering real-time technical guidance
  • Advanced assay platforms to promote the data output
  • Timely data feedback to facilitate the process of your project

Creative Biolabs is a leading company which is dedicated to helping our worldwide customers shorten the discovery and development time in CAR-T cell therapy. We utilize unrivaled, proprietary drug design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes. Through our full spectrum of early discovery, nonclinical and commercialization services, we are committed to developing the most promising CAR-T cell therapy product candidate for our clients.

For more detailed information, please feel free to contact us or directly send us an inquiry.


  1. Adachi K, Kano Y, Nagai T, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor[J]. Nature Biotechnology, 2018.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.